{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:10:00Z","timestamp":1772752200313,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T00:00:00Z","timestamp":1741478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T00:00:00Z","timestamp":1741478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sunshine Guojian Pharmaceutical (Shanghai) Co.,Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s13555-025-01368-4","type":"journal-article","created":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T12:52:56Z","timestamp":1741524776000},"page":"857-867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of 611 in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Phase II Trial"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct05544591","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Litao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinsuo","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingkai","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lunfei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangfeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haomin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,9]]},"reference":[{"issue":"5","key":"1368_CR1","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/CM9.0000000000002560","volume":"136","author":"D Mao","year":"2023","unstructured":"Mao D, Li J, Liu S, et al. Prevalence and risk factors of atopic dermatitis in Chinese adults: a nationwide population-based cross-sectional study. Chin Med J (Engl). 2023;136(5):604\u20136. https:\/\/doi.org\/10.1097\/CM9.0000000000002560.","journal-title":"Chin Med J (Engl)"},{"key":"1368_CR2","doi-asserted-by":"publisher","first-page":"29751","DOI":"10.1038\/srep29751","volume":"6","author":"Y Guo","year":"2016","unstructured":"Guo Y, Li P, Tang J, et al. Prevalence of atopic dermatitis in chinese children aged 1\u20137 years. Sci Rep. 2016;6:29751. https:\/\/doi.org\/10.1038\/srep29751.","journal-title":"Sci Rep"},{"issue":"1","key":"1368_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.1365-2249.1996.00911.x","volume":"103","author":"S Esnault","year":"1996","unstructured":"Esnault S, Benbernou N, Lavaud F, Shin HC, Potron G, Guenounou M. Differential spontaneous expression of mRNA for IL-4, IL-10, IL-13, IL-2 and interferon-gamma (IFN-gamma) in peripheral blood mononuclear cells (PBMC) from atopic patients. Clin Exp Immunol. 1996;103(1):111\u20138. https:\/\/doi.org\/10.1046\/j.1365-2249.1996.00911.x.","journal-title":"Clin Exp Immunol"},{"issue":"3 Pt 1","key":"1368_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/s0091-6749(05)80010-7","volume":"90","author":"K Jujo","year":"1992","unstructured":"Jujo K, Renz H, Abe J, Gelfand EW, Leung DY. Decreased interferon gamma and increased interleukin-4 production in atopic dermatitis promotes IgE synthesis. J Allergy Clin Immunol. 1992;90(3 Pt 1):323\u201331. https:\/\/doi.org\/10.1016\/s0091-6749(05)80010-7.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1368_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/s0923-1811(01)00174-8","volume":"29","author":"K Kaminishi","year":"2002","unstructured":"Kaminishi K, Soma Y, Kawa Y, Mizoguchi M. Flow cytometric analysis of IL-4, IL-13 and IFN-gamma expression in peripheral blood mononuclear cells and detection of circulating IL-13 in patients with atopic dermatitis provide evidence for the involvement of type 2 cytokines in the disease. J Dermatol Sci. 2002;29(1):19\u201325. https:\/\/doi.org\/10.1016\/s0923-1811(01)00174-8.","journal-title":"J Dermatol Sci"},{"issue":"3","key":"1368_CR6","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1084\/jem.168.3.853","volume":"168","author":"DA Lebman","year":"1988","unstructured":"Lebman DA, Coffman RL. Interleukin 4 causes isotype switching to IgE in T cell-stimulated clonal B cell cultures. J Exp Med. 1988;168(3):853\u201362. https:\/\/doi.org\/10.1084\/jem.168.3.853.","journal-title":"J Exp Med"},{"issue":"16","key":"1368_CR7","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.3390\/jcm12165370","volume":"12","author":"C Gu","year":"2023","unstructured":"Gu C, Yao X, Li W. Burden of disease; the current status of the diagnosis and management of atopic dermatitis in China. J Clin Med. 2023;12(16):5370. https:\/\/doi.org\/10.3390\/jcm12165370.","journal-title":"J Clin Med"},{"issue":"1","key":"1368_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217-228.e13. https:\/\/doi.org\/10.1016\/j.cell.2017.08.006.","journal-title":"Cell"},{"issue":"11","key":"1368_CR9","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1056\/NEJMc1700366","volume":"376","author":"M Mennini","year":"2017","unstructured":"Mennini M, Dahdah L, Fiocchi A. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2017;376(11):1090. https:\/\/doi.org\/10.1056\/NEJMc1700366.","journal-title":"N Engl J Med"},{"issue":"7","key":"1368_CR10","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/cea.13954","volume":"51","author":"JD Hamilton","year":"2021","unstructured":"Hamilton JD, Harel S, Swanson BN, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021;51(7):915\u201331. https:\/\/doi.org\/10.1111\/cea.13954.","journal-title":"Clin Exp Allergy"},{"issue":"19","key":"1368_CR11","doi-asserted-by":"publisher","first-page":"5633","DOI":"10.3390\/jcm11195633","volume":"11","author":"G Pappa","year":"2022","unstructured":"Pappa G, Sgouros D, Theodoropoulos K, et al. The IL-4\/-13 axis and its blocking in the treatment of atopic dermatitis. J Clin Med. 2022;11(19):5633. https:\/\/doi.org\/10.3390\/jcm11195633.","journal-title":"J Clin Med"},{"issue":"5","key":"1368_CR12","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc'h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188\u2013204. https:\/\/doi.org\/10.1111\/all.14151.","journal-title":"Allergy"},{"issue":"10086","key":"1368_CR13","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(17)31191-1.","journal-title":"Lancet"},{"issue":"1","key":"1368_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.anai.2023.03.014","volume":"131","author":"DJ Jackson","year":"2023","unstructured":"Jackson DJ, Bacharier LB, Phipatanakul W, et al. Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma. Ann Allergy Asthma Immunol. 2023;131(1):44-51.e4. https:\/\/doi.org\/10.1016\/j.anai.2023.03.014.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"1368_CR15","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.3390\/jcm12072701","volume":"12","author":"A Chiricozzi","year":"2023","unstructured":"Chiricozzi A, Maurelli M, Calabrese L, et al. Overview of atopic dermatitis in different ethnic groups. J Clin Med. 2023;12(7):2701. https:\/\/doi.org\/10.3390\/jcm12072701.","journal-title":"J Clin Med"},{"issue":"5","key":"1368_CR16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.anai.2018.11.015","volume":"122","author":"PM Brunner","year":"2019","unstructured":"Brunner PM, Guttman-Yassky E. Racial differences in atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122(5):449\u201355. https:\/\/doi.org\/10.1016\/j.anai.2018.11.015.","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01368-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01368-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01368-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T15:20:29Z","timestamp":1743866429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01368-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,9]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1368"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01368-4","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,9]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Haomin Huang, Qinghong Zhou, and Yuyu Xu are employees of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.; Yan Zhao, Litao Zhang, Liming Wu, Xinsuo Duan, Chao Ji, Rong Xiao, Mingkai Ji, Lunfei Liu, Bin Yang, Guohong Hu, Yanyan Feng, Jianjian Zhu, Jianguo Li, Yangfeng Ding, and Jianzhong Zhang have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study adhered to the ethical principles of the Declaration of Helsinki for medical research involving human subjects and was conducted in accordance with Good Clinical Practice (GCP) guidelines. Before the study commenced, the clinical trial protocol, case report forms, informed consent forms, and other related documents were approved by the Peking University People\u2019s Hospital Ethics Committee (approval number: 2022PHC022-001). All patients provided written informed consent for participation in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}